CVS Health stock heads into Q3 results with mixed outlook
Published on 11/02/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings Test Puts Guidance In Focus
- CVS Health is scheduled to report third-quarter results before the US market opens on Wednesday, November 4.
- Analysts expect mixed segment trends as Aetna margin recovery competes with medical-cost and 340B pressure.
- Management commentary on 2027 priorities may matter as much as the quarterly figures.
CVS Health is due to release third-quarter 2026 results before US markets open on Wednesday, November 4. The report will test whether improving insurance economics can offset pressure in pharmacy services and medical costs.
In its earnings preview published October 26, Zacks Investment Research projected third-quarter adjusted earnings of USD 1.62 per share and revenue of USD 105.04 billion. The estimates imply modest year-over-year growth, while Zacks said the forecast had remained unchanged over the previous 60 days.
Mixed Trends Across Core Businesses
Zacks expects Aetna's margin recovery and strength in the Government business to support Health Care Benefits. Elevated medical-cost utilization and the company's exit from the individual exchange business remain potential offsets.
Health Services may benefit from pharmacy drug mix, purchasing economics and growth at Oak Street Health. The Caremark pharmacy benefit manager still faces pressure in its 340B business, where program changes and contract dynamics could weigh on performance.
Pharmacy and Consumer Wellness may receive support from prescription volume, brand inflation and the Rite Aid transaction. Regulatory price reductions, generic-drug introductions and reimbursement pressure could limit the benefit.
Guidance Remains The Next Catalyst
Management's comments on fourth-quarter guidance, cost reduction, capital allocation and 2027 priorities may influence investors' assessment of the earnings quality. Zacks also highlighted CVS Health's technology investment and digital initiatives, while warning that 340B-related pressure could remain a near-term headwind.
The real-time quote of CVS Health stock was EUR 79.54 at Lang & Schwarz at 15:35 CET on Monday, November 2. That was 1.73% below the EUR 80.94 quote cited in the previous report published November 1; this comparison is separate from the daily Xetra close comparison.
CVS Health Corp. stock facts
- Company: CVS Health Corp.
- ISIN: US1266501006
- Ticker: CVS
- Lang & Schwarz price: EUR 79.54 at 15:35 CET on November 2, 2026
- Prior own-report quote: EUR 80.94 on November 1, 2026
Broader market sentiment will also influence attention around the S&P 500.
More news and analyses on CVS Health stock will follow the November 4 results and management's outlook.
